Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis: A randomized, controlled trial

Jackson THOMAS, C Narkowicz, Glenn Jacobson, Gregory Peterson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

What is known and objective Anecdotally, topical kunzea oil has been used to treat various skin conditions, including psoriasis and eczema, with good results. This study compared the clinical efficacy of kunzea oil (20%)-containing formulations in mild to moderate psoriasis. Methods A randomized, comparative, double-blind, 8-week study was undertaken. Thirty patients (age range: 25-74 years and mean ± SD: 52·8 ± 13·6 years) with mild to moderate psoriasis (affecting at least 10% of one or more body regions: arms, head, legs and trunk) randomly received ointment and/or scalp lotion containing 20% kunzea oil (test group) or control medications not containing kunzea oil (control group). Formulations in both treatment arms also contained 5% liquor carbonis detergens (LCD) and 3% salicylic acid. The clinical responses to the test and control formulations were evaluated using the Psoriasis Area and Severity Index (PASI). Results and discussion After 8 weeks of treatment, both test and control groups demonstrated a significant (P <0·05) improvement in PASI scores. Subjects in the test group had a decrease in mean±SD PASI score from 12·7 ± 7·9 to 6·7 ± 7·2, whereas the control group showed a decrease in PASI score from 8·1 ± 4·6 to 3·5 ± 4·7. Comparative efficacy analysis between the test and control groups did not reveal any significant difference (P > 0·05). What is new and conclusions The inclusion of kunzea oil made no difference to the efficacy of topical formulations containing LCD and salicylic acid for the treatment of psoriasis. Our study showed that both trialled treatment formulations were safe and effective in managing mild to moderate cases of psoriasis. However, the current results do not support the use of kunzea oil containing formulations for the management of psoriasis.
Original languageEnglish
Pages (from-to)566-572
Number of pages7
JournalJournal of Clinical Pharmacy and Therapeutics
Volume40
Issue number5
DOIs
Publication statusPublished - 2015

Fingerprint

Kunzea
Psoriasis
Oils
Randomized Controlled Trials
Safety
Salicylic Acid
Control Groups
Arm
Body Regions
Eczema
Therapeutics
Ointments
Scalp
Leg
Head

Cite this

@article{93d068586b1445c189e0096c2696c6e0,
title = "Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis: A randomized, controlled trial",
abstract = "What is known and objective Anecdotally, topical kunzea oil has been used to treat various skin conditions, including psoriasis and eczema, with good results. This study compared the clinical efficacy of kunzea oil (20{\%})-containing formulations in mild to moderate psoriasis. Methods A randomized, comparative, double-blind, 8-week study was undertaken. Thirty patients (age range: 25-74 years and mean ± SD: 52·8 ± 13·6 years) with mild to moderate psoriasis (affecting at least 10{\%} of one or more body regions: arms, head, legs and trunk) randomly received ointment and/or scalp lotion containing 20{\%} kunzea oil (test group) or control medications not containing kunzea oil (control group). Formulations in both treatment arms also contained 5{\%} liquor carbonis detergens (LCD) and 3{\%} salicylic acid. The clinical responses to the test and control formulations were evaluated using the Psoriasis Area and Severity Index (PASI). Results and discussion After 8 weeks of treatment, both test and control groups demonstrated a significant (P <0·05) improvement in PASI scores. Subjects in the test group had a decrease in mean±SD PASI score from 12·7 ± 7·9 to 6·7 ± 7·2, whereas the control group showed a decrease in PASI score from 8·1 ± 4·6 to 3·5 ± 4·7. Comparative efficacy analysis between the test and control groups did not reveal any significant difference (P > 0·05). What is new and conclusions The inclusion of kunzea oil made no difference to the efficacy of topical formulations containing LCD and salicylic acid for the treatment of psoriasis. Our study showed that both trialled treatment formulations were safe and effective in managing mild to moderate cases of psoriasis. However, the current results do not support the use of kunzea oil containing formulations for the management of psoriasis.",
keywords = "Kunzea oil, essential oil, liquor carbonis detergens, psoriasis, randomized controlled clinical trial, salicylic acid",
author = "Jackson THOMAS and C Narkowicz and Glenn Jacobson and Gregory Peterson",
year = "2015",
doi = "10.1111/jcpt.12311",
language = "English",
volume = "40",
pages = "566--572",
journal = "Journal of Clinical and Hospital Pharmacy",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "5",

}

Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis: A randomized, controlled trial. / THOMAS, Jackson; Narkowicz, C; Jacobson, Glenn; Peterson, Gregory.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 40, No. 5, 2015, p. 566-572.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and efficacy of kunzea oil-containing formulations for the management of psoriasis: A randomized, controlled trial

AU - THOMAS, Jackson

AU - Narkowicz, C

AU - Jacobson, Glenn

AU - Peterson, Gregory

PY - 2015

Y1 - 2015

N2 - What is known and objective Anecdotally, topical kunzea oil has been used to treat various skin conditions, including psoriasis and eczema, with good results. This study compared the clinical efficacy of kunzea oil (20%)-containing formulations in mild to moderate psoriasis. Methods A randomized, comparative, double-blind, 8-week study was undertaken. Thirty patients (age range: 25-74 years and mean ± SD: 52·8 ± 13·6 years) with mild to moderate psoriasis (affecting at least 10% of one or more body regions: arms, head, legs and trunk) randomly received ointment and/or scalp lotion containing 20% kunzea oil (test group) or control medications not containing kunzea oil (control group). Formulations in both treatment arms also contained 5% liquor carbonis detergens (LCD) and 3% salicylic acid. The clinical responses to the test and control formulations were evaluated using the Psoriasis Area and Severity Index (PASI). Results and discussion After 8 weeks of treatment, both test and control groups demonstrated a significant (P <0·05) improvement in PASI scores. Subjects in the test group had a decrease in mean±SD PASI score from 12·7 ± 7·9 to 6·7 ± 7·2, whereas the control group showed a decrease in PASI score from 8·1 ± 4·6 to 3·5 ± 4·7. Comparative efficacy analysis between the test and control groups did not reveal any significant difference (P > 0·05). What is new and conclusions The inclusion of kunzea oil made no difference to the efficacy of topical formulations containing LCD and salicylic acid for the treatment of psoriasis. Our study showed that both trialled treatment formulations were safe and effective in managing mild to moderate cases of psoriasis. However, the current results do not support the use of kunzea oil containing formulations for the management of psoriasis.

AB - What is known and objective Anecdotally, topical kunzea oil has been used to treat various skin conditions, including psoriasis and eczema, with good results. This study compared the clinical efficacy of kunzea oil (20%)-containing formulations in mild to moderate psoriasis. Methods A randomized, comparative, double-blind, 8-week study was undertaken. Thirty patients (age range: 25-74 years and mean ± SD: 52·8 ± 13·6 years) with mild to moderate psoriasis (affecting at least 10% of one or more body regions: arms, head, legs and trunk) randomly received ointment and/or scalp lotion containing 20% kunzea oil (test group) or control medications not containing kunzea oil (control group). Formulations in both treatment arms also contained 5% liquor carbonis detergens (LCD) and 3% salicylic acid. The clinical responses to the test and control formulations were evaluated using the Psoriasis Area and Severity Index (PASI). Results and discussion After 8 weeks of treatment, both test and control groups demonstrated a significant (P <0·05) improvement in PASI scores. Subjects in the test group had a decrease in mean±SD PASI score from 12·7 ± 7·9 to 6·7 ± 7·2, whereas the control group showed a decrease in PASI score from 8·1 ± 4·6 to 3·5 ± 4·7. Comparative efficacy analysis between the test and control groups did not reveal any significant difference (P > 0·05). What is new and conclusions The inclusion of kunzea oil made no difference to the efficacy of topical formulations containing LCD and salicylic acid for the treatment of psoriasis. Our study showed that both trialled treatment formulations were safe and effective in managing mild to moderate cases of psoriasis. However, the current results do not support the use of kunzea oil containing formulations for the management of psoriasis.

KW - Kunzea oil

KW - essential oil

KW - liquor carbonis detergens

KW - psoriasis

KW - randomized controlled clinical trial

KW - salicylic acid

UR - http://www.scopus.com/inward/record.url?scp=84941023797&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/safety-efficacy-kunzea-oilcontaining-formulations-management-psoriasis-randomized-controlled-trial

U2 - 10.1111/jcpt.12311

DO - 10.1111/jcpt.12311

M3 - Article

VL - 40

SP - 566

EP - 572

JO - Journal of Clinical and Hospital Pharmacy

JF - Journal of Clinical and Hospital Pharmacy

SN - 0269-4727

IS - 5

ER -